Trial · NCT01259089
Adverse events780
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
101 to 120 of 780
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Gastroesophageal reflux disease | Gastrointestinal disorders | Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | 6 | |
| other | Gastroesophageal reflux disease | Gastrointestinal disorders | Phase II- 70 mg/m2 AUY922+150 mg Daily Erlotinib | 1 | 19 | |
| other | Hemorrhoids | Gastrointestinal disorders | Cohort 1 - 25 mg/m2 AUY922+75 mg Daily Erlotinib | 0 | 3 | |
| other | Hemorrhoids | Gastrointestinal disorders | Cohort 2 - 25 mg/m2AUY922+150 mg Daily Erlotinib | 1 | 3 | |
| other | Hemorrhoids | Gastrointestinal disorders | Cohort 3 - 37.5 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | 3 | |
| other | Hemorrhoids | Gastrointestinal disorders | Cohort 4 - 55 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | 3 | |
| other | Hemorrhoids | Gastrointestinal disorders | Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | 6 | |
| other | Hemorrhoids | Gastrointestinal disorders | Phase II- 70 mg/m2 AUY922+150 mg Daily Erlotinib | 1 | 19 | |
| other | Mucositis oral | Gastrointestinal disorders | Cohort 1 - 25 mg/m2 AUY922+75 mg Daily Erlotinib | 0 | 3 | |
| other | Mucositis oral | Gastrointestinal disorders | Cohort 2 - 25 mg/m2AUY922+150 mg Daily Erlotinib | 0 | 3 | |
| other | Mucositis oral | Gastrointestinal disorders | Cohort 3 - 37.5 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | 3 | |
| other | Mucositis oral | Gastrointestinal disorders | Cohort 4 - 55 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | 3 | |
| other | Mucositis oral | Gastrointestinal disorders | Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib | 1 | 6 | |
| other | Mucositis oral | Gastrointestinal disorders | Phase II- 70 mg/m2 AUY922+150 mg Daily Erlotinib | 5 | 19 | |
| other | Nausea | Gastrointestinal disorders | Cohort 1 - 25 mg/m2 AUY922+75 mg Daily Erlotinib | 2 | 3 | |
| other | Nausea | Gastrointestinal disorders | Cohort 2 - 25 mg/m2AUY922+150 mg Daily Erlotinib | 2 | 3 | |
| other | Nausea | Gastrointestinal disorders | Cohort 3 - 37.5 mg/m2 AUY922+150 mg Daily Erlotinib | 3 | 3 | |
| other | Nausea | Gastrointestinal disorders | Cohort 4 - 55 mg/m2 AUY922+150 mg Daily Erlotinib | 1 | 3 | |
| other | Nausea | Gastrointestinal disorders | Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib | 2 | 6 | |
| other | Nausea | Gastrointestinal disorders | Phase II- 70 mg/m2 AUY922+150 mg Daily Erlotinib | 7 | 19 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01259089/events?page=6